{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:41:53Z","timestamp":1790138513624,"version":"4.0.1"},"reference-count":85,"publisher":"Oxford University Press (OUP)","issue":"1096","license":[{"start":{"date-parts":[[2016,10,8]],"date-time":"2016-10-08T00:00:00Z","timestamp":1475884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,2,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Certain cancer therapies, including radiation therapy and some types of chemotherapies, are associated with increased risk of cardiovascular disease (CVD) and events. Some of these effects such as those presented by anthracyclines, radiation therapy, cisplatin, as well as those presented by hormone therapy for breast cancer\u2014usually taken for many years for some breast and prostate cancers\u2014are long-lasting and associated with cardiovascular events risk more than 20\u2005years after cancer treatment. Cardiovascular testing, diagnostic assessment of suspected cardiovascular symptomatology, as well as laboratory tests for CVD risk factors are imperative. The early recognition and treatment of CVD processes that arise in survivorship years is pivotal, with specific attention to some CVD processes with specific suggested treatment modalities. Preventive measures include adequate screening, the use of medications such as ACE inhibitors\/angiotensin receptor blockers and\/or beta blockers, statin therapy and aspirin in persons who warrant these medications, as well as therapeutic lifestyle modifications such as exercise\/physical activity, weight loss and appropriate diet for a healthy lifestyle. Periodic follow-up with a good primary care physician who understands the risks associated with cancer therapy is important, and referral to onco-cardiology for further management of cardiovascular risk in these survivors is based on a patient\u2019s cardiovascular risk level and the type, amount and duration of cancer therapies received during the patient\u2019s lifetime.<\/jats:p>","DOI":"10.1136\/postgradmedj-2016-134417","type":"journal-article","created":{"date-parts":[[2016,10,9]],"date-time":"2016-10-09T00:58:15Z","timestamp":1475974695000},"page":"82-90","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":92,"title":["Cardiovascular disease in cancer survivors"],"prefix":"10.1093","volume":"93","author":[{"given":"Tochi M","family":"Okwuosa","sequence":"first","affiliation":[{"name":"Division of Cardiology, Rush University Medical Center , Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Anzevino","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Cell Therapy, Rush University Medical Center , Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruta","family":"Rao","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Cell Therapy, Rush University Medical Center , Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,10,8]]},"reference":[{"key":"2023041308091827500_","volume-title":"Cancer treatment and survivorship facts and figures 2014\u20142015","author":"American Cancer Society","year":"2014"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/jnci\/djn310","article-title":"Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study","volume":"100","author":"Mertens","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"R64","DOI":"10.1186\/bcr2901","article-title":"Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study","volume":"13","author":"Patnaik","year":"2011","journal-title":"Breast Cancer Res"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1200\/JCO.2008.21.1425","article-title":"Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study","volume":"27","author":"Armstrong","year":"2009","journal-title":"J Clin Oncol"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/ijc.30080","article-title":"Cause-specific long-term mortality in survivors of childhood cancer in Switzerland: a population based study","volume":"139","author":"Schindler","year":"2016","journal-title":"Int J Cancer"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/ijc.10981","article-title":"Health profiles in 5836 long-term cancer survivors","volume":"104","author":"Schultz","year":"2003","journal-title":"Int J Cancer"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMsa060185","article-title":"Chronic health conditions in adult survivors of childhood cancer","volume":"355","author":"Oeffinger","year":"2006","journal-title":"N Engl J Med"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1021\/tx800002r","article-title":"Cardiotoxicity of antitumor drugs","volume":"21","author":"Menna","year":"2008","journal-title":"Chem Res Toxicol"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.seminoncol.2013.01.008","article-title":"Strategies to prevent and treat cardiovascular risk in cancer patients","volume":"40","author":"Cardinale","year":"2013","journal-title":"Semin Oncol"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jama.2010.923","article-title":"Long-term cause-specific mortality among survivors of childhood cancer","volume":"304","author":"Reulen","year":"2010","journal-title":"JAMA"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jama.1991.03470120074036","article-title":"Cardiac toxicity 4 to 20 years after completing anthracycline therapy","volume":"266","author":"Steinherz","year":"1991","journal-title":"JAMA"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/0002-9343(77)90315-1","article-title":"Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases","volume":"62","author":"Von Hoff","year":"1977","journal-title":"Am J Med"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2217\/fca.12.44","article-title":"Cardiotoxicity in childhood cancer survivors: strategies for prevention and management","volume":"8","author":"Harake","year":"2012","journal-title":"Future Cardiol"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJM199103213241205","article-title":"Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood","volume":"324","author":"Lipshultz","year":"1991","journal-title":"N Engl J Med"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/jnci\/djs317","article-title":"Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study","volume":"104","author":"Bowles","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","article-title":"Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity","volume":"23","author":"Ewer","year":"2005","journal-title":"J Clin Oncol"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1080\/21645515.2015.1125056","article-title":"Trastuzumab and target-therapy side effects: is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?","volume":"12","author":"Riccio","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2165\/00002018-200831060-00002","article-title":"Cardiotoxicity profile of trastuzumab","volume":"31","author":"Ewer","year":"2008","journal-title":"Drug Saf"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1200\/JCO.2010.31.9129","article-title":"Congestive heart failure risk in patients with breast cancer treated with bevacizumab","volume":"29","author":"Choueiri","year":"2011","journal-title":"J Clin Oncol"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J Clin Oncol"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/eurjhf\/hft008","article-title":"The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors","volume":"15","author":"Tocchetti","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1158\/1078-0432.CCR-15-0215","article-title":"Effects of adjuvant sorafenib and sunitinib on cardiac function in renal cell carcinoma patients without overt metastases: results from ASSURE, ECOG 2805","volume":"21","author":"Haas","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/bcp.12387","article-title":"Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials","volume":"78","author":"Qi","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","article-title":"Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study","volume":"16","author":"Tabernero","year":"2015","journal-title":"Lancet Oncol"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","article-title":"Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma","volume":"26","author":"Schmidinger","year":"2008","journal-title":"J Clin Oncol"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdp025","article-title":"Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis","volume":"20","author":"Di Lorenzo","year":"2009","journal-title":"Ann Oncol"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1002\/cncr.23460","article-title":"Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor","volume":"112","author":"Khakoo","year":"2008","journal-title":"Cancer"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/annonc\/mdn168","article-title":"Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate","volume":"19","author":"Telli","year":"2008","journal-title":"Ann Oncol"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1472-6904-8-7","article-title":"Long-term platinum retention after treatment with cisplatin and oxaliplatin","volume":"8","author":"Brouwers","year":"2008","journal-title":"BMC Clin Pharmacol"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.2165\/00003495-200363150-00004","article-title":"Long-term complications of chemotherapy for germ cell tumours","volume":"63","author":"Chaudhary","year":"2003","journal-title":"Drugs"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2010.29.9362","article-title":"Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study","volume":"28","author":"Haugnes","year":"2010","journal-title":"J Clin Oncol"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.breast.2013.01.014","article-title":"Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women","volume":"22","author":"Aydiner","year":"2013","journal-title":"Breast"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0140-6736(03)12342-2","article-title":"Overview of the main outcomes in breast-cancer prevention trials","volume":"361","author":"Cuzick","year":"2003","journal-title":"Lancet"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1161\/01.CIR.0000154545.84124.AC","article-title":"Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial","volume":"111","author":"Decensi","year":"2005","journal-title":"Circulation"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/jama.2009.1137","article-title":"Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction","volume":"302","author":"Nanda","year":"2009","journal-title":"JAMA"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/cncr.25597","article-title":"Coronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivation","volume":"117","author":"Nguyen","year":"2011","journal-title":"Cancer"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"417673","DOI":"10.1155\/2012\/417673","article-title":"Bevacizumab and breast cancer: a meta-analysis of first-line phase III studies and a critical reappraisal of available evidence","volume":"2012","author":"Rossari","year":"2012","journal-title":"J Oncol"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"103","author":"Rini","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ahj.2011.10.018","article-title":"Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"163","author":"Steingart","year":"2012","journal-title":"Am Heart J"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1200\/JCO.2005.02.176","article-title":"The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer","volume":"23","author":"Nuver","year":"2005","journal-title":"J Clin Oncol"},{"key":"2023041308091827500_","first-page":"4980","article-title":"Blood pressure and body mass index in long-term survivors of testicular cancer","volume-title":"J Clin Oncol","author":"Sagstuen","year":"2005"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"967826","DOI":"10.1155\/2014\/967826","article-title":"Pathophysiology of cisplatin-induced acute kidney injury","volume":"2014","author":"Ozkok","year":"2014","journal-title":"Biomed Res Int"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(10)62312-4","article-title":"Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial","volume":"377","author":"van de Velde","year":"2011","journal-title":"Lancet"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1177\/2047487314529348","article-title":"Prevalence of cardiovascular risk factors in long-term survivors of childhood cancer: 16 years follow up from a prospective registry","volume":"22","author":"Felicetti","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1158\/1055-9965.EPI-09-0555","article-title":"Cardiovascular risk factors in adult survivors of pediatric cancer\u2014a report from the childhood cancer survivor study","volume":"19","author":"Meacham","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1200\/JCO.2000.18.8.1725","article-title":"Cardiovascular morbidity in long-term survivors of metastatic testicular cancer","volume":"18","author":"Meinardi","year":"2000","journal-title":"J Clin Oncol"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/sj.bjc.6600714","article-title":"Excessive annual BMI increase after chemotherapy among young survivors of testicular cancer","volume":"88","author":"Nord","year":"2003","journal-title":"Br J Cancer"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.2009.23.1274","article-title":"Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen","volume":"28","author":"Dowsett","year":"2010","journal-title":"J Clin Oncol"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","article-title":"A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer","volume":"353","author":"Thurlimann","year":"2005","journal-title":"N Engl J Med"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1161\/01.CIR.0000133187.74800.B9","article-title":"Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management","volume":"109","author":"Yeh","year":"2004","journal-title":"Circulation"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S1470-2045(05)70251-5","article-title":"Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries","volume":"6","author":"Darby","year":"2005","journal-title":"Lancet Oncol"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2407-7-9","article-title":"Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based study","volume":"7","author":"Roychoudhuri","year":"2007","journal-title":"BMC Cancer"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.echo.2013.07.005","article-title":"Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography","volume":"26","author":"Lancellotti","year":"2013","journal-title":"J Am Soc Echocardiogr"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jacc.2014.11.035","article-title":"Abnormal exercise response in long-term survivors of Hodgkin lymphoma treated with thoracic irradiation: evidence of cardiac autonomic dysfunction and impact on outcomes","volume":"65","author":"Groarke","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1056\/NEJMoa1209825","article-title":"Ischemic heart disease after breast cancer radiotherapy","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.ijrobp.2015.12.018","article-title":"Modern radiation therapy and cardiac outcomes in breast cancer","volume":"94","author":"Boero","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J Am Soc Echocardiogr"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab","volume":"5","author":"Sawaya","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1016\/j.ejca.2013.06.046","article-title":"Left ventricular systolic function in HER2\/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months","volume":"49","author":"Stoodley","year":"2013","journal-title":"Eur J Cancer"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1200\/JCO.2006.07.0805","article-title":"Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease","volume":"25","author":"Heidenreich","year":"2007","journal-title":"J Clin Oncol"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy","volume":"55","author":"Cardinale","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/HYPERTENSIONAHA.109.129973","article-title":"Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression","volume":"54","author":"Facemire","year":"2009","journal-title":"Hypertension"},{"key":"2023041308091827500_","first-page":"3465","article-title":"Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab","volume":"27","author":"Pande","year":"2007","journal-title":"Anticancer Res"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s10637-010-9549-5","article-title":"Treatment of bevacizumab-induced hypertension by amlodipine","volume":"30","author":"Mir","year":"2012","journal-title":"Invest New Drugs"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jacc.2009.11.053","article-title":"Understanding radiation-induced vascular disease","volume":"55","author":"Weintraub","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1586\/14779072.6.10.1311","article-title":"Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity","volume":"6","author":"Jones","year":"2008","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","article-title":"Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies)","volume":"61","author":"Bosch","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1056\/NEJMoa1201735","article-title":"Statin use and reduced cancer-related mortality","volume":"367","author":"Nielsen","year":"2012","journal-title":"N Engl J Med"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.jacc.2012.07.067","article-title":"Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study","volume":"60","author":"Seicean","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.clbc.2016.02.006","article-title":"Clinical outcomes and toxicity of proton radiotherapy for breast cancer","volume":"16","author":"Verma","year":"2016","journal-title":"Clin Breast Cancer"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.mito.2014.10.008","article-title":"Physical exercise prior and during treatment reduces sub-chronic doxorubicin-induced mitochondrial toxicity and oxidative stress","volume":"20","author":"Marques-Aleixo","year":"2015","journal-title":"Mitochondrion"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1200\/JCO.2014.56.7511","article-title":"Exercise and risk of major cardiovascular events in adult survivors of childhood Hodgkin lymphoma: a report from the childhood cancer survivor study","volume":"32","author":"Jones","year":"2014","journal-title":"J Clin Oncol"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1001\/jama.1993.03510160067031","article-title":"Factors affecting late mortality from heart disease after treatment of Hodgkin's disease","volume":"270","author":"Hancock","year":"1993","journal-title":"JAMA"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0735-1097(03)00759-9","article-title":"Asymptomatic cardiac disease following mediastinal irradiation","volume":"42","author":"Heidenreich","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2023041308091827500_","first-page":"219","article-title":"Post-radiation valvular and coronary artery disease","volume":"6","author":"Gonzaga","year":"1997","journal-title":"J Heart Valve Dis"},{"key":"2023041308091827500_","first-page":"883","article-title":"Radiation-associated valvular heart disease","volume":"22","author":"Ong","year":"2013","journal-title":"J Heart Valve Dis"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/CRD.0b013e3182431c23","article-title":"Radiation-induced heart disease","volume":"20","author":"Filopei","year":"2012","journal-title":"Cardiol Rev"},{"key":"2023041308091827500_","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/j.jacc.2013.01.090","article-title":"Cardiac complications of thoracic irradiation","volume":"61","author":"Jaworski","year":"2013","journal-title":"J Am Coll Cardiol"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/93\/1096\/82\/49839651\/postgradmedj-93-82.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/93\/1096\/82\/49839651\/postgradmedj-93-82.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T21:01:58Z","timestamp":1718830918000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/93\/1096\/82\/6984149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,8]]},"references-count":85,"journal-issue":{"issue":"1096","published-online":{"date-parts":[[2016,10,8]]},"published-print":{"date-parts":[[2017,2,1]]}},"URL":"https:\/\/doi.org\/10.1136\/postgradmedj-2016-134417","relation":{},"ISSN":["1469-0756","0032-5473"],"issn-type":[{"value":"1469-0756","type":"electronic"},{"value":"0032-5473","type":"print"}],"subject":[],"published-other":{"date-parts":[[2017,2]]},"published":{"date-parts":[[2016,10,8]]}}}